RESUMEN
Coronaviruses are a common class of respiratory viruses that can cause human infections. 2019 novel coronavirus(2019-nCoV), a new coronavirus that has recently caused a pandemic, has affected millions of people and put tremendous pressure on the health systems of almost every country in the world. Coronaviruses are known to spread from person to person through droplets or contact. The 2019-nCoV has also been found in the conjunctival secretions and tears of some clinically diagnosed patients. To assess whether the eye is one of the transmission routes of the virus, we review literature, and summarize the anatomy of the eye-nose pathway, the expression of the virus receptor in the eye, the preclinical animal studies, and the clinical data. We analyze the possibility of eyes as a means of transmission and propose some suggestions of ocular protection. (Chin J Ophthalmol, 2021, 57: 305-310).
Asunto(s)
COVID-19 , Infecciones por Coronavirus , Coronavirus , Animales , Humanos , Pandemias , SARS-CoV-2RESUMEN
Large cohort studies have revealed a close relationship between cognitive impairment and cardiovascular diseases, although the mechanism underlying this relationship remains incompletely understood. In this study, using a transgenic (Tg) mouse model of cardiac-specific over-expression of microRNA-1-2 (miR-1-2), we observed that microRNA-1 (miR-1) levels were increased not only in the heart but also in the hippocampus and blood, whereas its levels did not change in the skeletal muscle of Tg mice compared with age-matched wild-type (WT) mice. Six-month-old Tg mice showed cognitive impairment compared with age-matched WT mice, as assessed using the Morris Water Maze test. The brain-derived neurotrophic factor (BDNF) level and cyclic AMP-responsive element-binding protein (CREB) phosphorylation were also significantly reduced in the hippocampi of the Tg mice, as evaluated by Western blot. Further examination showed that BDNF protein expression was down- or up-regulated by miR-1 over-expression or inhibition, respectively, and was unchanged by binding site mutations or miRNA-masks for the 3'UTR of Bdnf, indicating that this gene is a potential target of miR-1. Knockdown of miR-1 by hippocampal stereotaxic injection of an anti-miR-1 oligonucleotide fragment carried by a lentivirus vector (lenti-pre-AMO-miR-1) led to up-regulation of BDNF expression and prevented the reduction in cognitive performance in the Tg mice without affecting cardiac function. Our findings demonstrate that cardiac over-expression of miR-1 also induces behavioral abnormalities that may be associated, at least in part, with the down-regulation of BDNF expression in the hippocampus. This study definitely contributes to the understanding of the relationship between cardiovascular disease and cognitive impairment.
Asunto(s)
Enfermedades Cardiovasculares/complicaciones , Trastornos del Conocimiento/metabolismo , MicroARNs/metabolismo , Animales , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Enfermedades Cardiovasculares/metabolismo , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/genética , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Modelos Animales de Enfermedad , Hipocampo/metabolismo , Masculino , Aprendizaje por Laberinto/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , MicroARNs/sangre , MicroARNs/genética , Músculo Esquelético/metabolismo , Miocardio/metabolismoRESUMEN
The disposition kinetics and metabolism of nicotine-1'-N-oxide (NNO) are of interest as the reduction of NNO might influence the pharmacokinetics of nicotine in tobacco users. The disposition kinetics of nicotine-1'-N-oxide were characterized in New Zealand rabbits. The clearance of NNO averaged 7.5 ml/min/kg. The half-life averaged 42.6 min and VDss was 0.34 liter/kg. The oral and ip bioavailabilities were 15.1 and 79%, respectively. NNO was reduced to nicotine and cotinine following i.v., oral, and ip injection. The pattern of metabolites after iv dosing suggests that there is systemic reduction of NNO, although the magnitude of that reduction is small, with less than 3% reduced to nicotine. Following oral NNO, 45% was reduced, with a metabolite pattern consistent with presystemic (bacterial or intestinal) metabolism.